3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Neuroendocrine Tumors
7
Carcinoma, Neuroendocrine
6
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Lung Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Non-Small-Cell Lung
2
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroendocrine Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Extrapulmonary Neuroendocrine Cancer
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Central Nervous System Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Large Cell
1
Interventions
Magnetic Resonance Spectroscopy
10
Paclitaxel
7
Iodine-131
6
Fluorodeoxyglucose F18
6
Sorafenib
5
vandetanib
4
trametinib
4
selpercatinib
4
dabrafenib
4
pembrolizumab
3
fosbretabulin
3
cabozantinib
3
Vemurafenib
3
Sunitinib
3
Specimen Handling
3
Nivolumab
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tipifarnib
2
romidepsin
2
pazopanib
2
lenvatinib
2
combretastatin
2
Trastuzumab
2
Thyrotropin Alfa
2
Ipilimumab
2
Gefitinib
2
FAPI-46
2
Everolimus
2
Doxorubicin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Carboplatin
×
Endocrine
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn